HLS vs. CPH, ACB, WEED, FIRE, OGI, EPI, ICC, RIV, LEAF, and RX
Should you be buying HLS Therapeutics stock or one of its competitors? The main competitors of HLS Therapeutics include Cipher Pharmaceuticals (CPH), Aurora Cannabis (ACB), Canopy Growth (WEED), Supreme Cannabis (FIRE), Organigram (OGI), ESSA Pharma (EPI), ICC Labs (ICC), RIV Capital (RIV), Leaf Mobile (LEAF), and BioSyent (RX). These companies are all part of the "drug manufacturers - specialty & generic" industry.
HLS Therapeutics vs.
HLS Therapeutics (TSE:HLS) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability, dividends and community ranking.
HLS Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Cipher Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
Cipher Pharmaceuticals received 147 more outperform votes than HLS Therapeutics when rated by MarketBeat users. However, 65.38% of users gave HLS Therapeutics an outperform vote while only 62.20% of users gave Cipher Pharmaceuticals an outperform vote.
65.2% of HLS Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Cipher Pharmaceuticals shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Cipher Pharmaceuticals has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cipher Pharmaceuticals has a net margin of 102.01% compared to HLS Therapeutics' net margin of -40.90%. Cipher Pharmaceuticals' return on equity of 28.43% beat HLS Therapeutics' return on equity.
HLS Therapeutics currently has a consensus target price of C$4.13, suggesting a potential upside of 3.38%. Cipher Pharmaceuticals has a consensus target price of C$12.50, suggesting a potential downside of 10.78%. Given HLS Therapeutics' higher probable upside, analysts clearly believe HLS Therapeutics is more favorable than Cipher Pharmaceuticals.
In the previous week, HLS Therapeutics' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.
Summary
Cipher Pharmaceuticals beats HLS Therapeutics on 12 of the 16 factors compared between the two stocks.
Get HLS Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HLS Therapeutics Competitors List
Related Companies and Tools
This page (TSE:HLS) was last updated on 1/19/2025 by MarketBeat.com Staff
